Home Office, Canada
2 Lansing Square, Toronto, ON M2J 4P8 tel.
Responses to Toronto Star Questions, May 5, 2014
The Leukemia & Lymphoma Society of Canada (LLSC), headquartered in Toronto, Ontario, is affiliated with The Leukemia & Lymphoma Society (LLS), headquartered in White Plains, NY, USA, as of July 1, 2004. LLSC and LLS fund research to advance innovative, life-saving therapies; support patients, caregivers and healthcare professionals through free blood cancer information, education and support; and promote policies that help patients have access to quality, affordable and coordinated care. LLSC and LLS touch patients through our 5 regional offices across Canada and 56 chapters in the U.S. The shared mission of the two organizations is
to cure leukemia, lymphoma, Hodgkin’s disease and myeloma and improve the quality of life for
patients and their families.
To start off, could you please tell us, in as simple language as possible, how much of the
money raised by Canadian donors goes to the charity’s good works? Following that, could you
please address the specific questions below?
Based on CRA data, the average fundraising cost ratio for the ten largest Canadian health charities in 2013 was 41%. Our fundraising ratio as per our 2013 T3010 was 35%, with 57% going to mission and 8% to administration costs. The CRA says that a fundraising ratio over 70% i
s “a cause for concern” and we are far under that threshold
We would like to know how much of those donor dollars goes to research. The LLSC’s most
recent online T3010 states approximately $1.7 million was given to research. Your website states more than $6 million was given to research in 2012. Could you please specify where the $6 million comes from? Also, if it is $1.7 million given to research by the LLSC, that is about 11 per cent of total dollars raised in Canada. Considering the stated primary mission of the charity is to cure blood cancers, can you please explain this percentage?
The mission of LLSC is to: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Our strategy to achieve the mission is based on three areas of focus: research, patient support and advocacy. In 2013 we spent over $4.1 million on public education programs, over $2.8 million on patient support and over $1.8 million on research. Largely because of our strong relationship with our U.S. affiliate The Leukemia & Lymphoma Society (LLS), Canadian scientists were also able to attract over $4 million in international funding for a total research investment of over $6 million. This reporting method for research investments is an industry standard that is endorsed by watchdog organizations like